ArticleThe American journal of hospice & palliative care2025
"
Article in The American journal of hospice & palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
IntroductionCaring for a child with a rare disease frequently involves making difficult medical decisions with limited disease-specific information. Advance care planning can assist families in articulating their values and treatment preferences. We aimed to describe parental treatment preferences for life-sustaining therapies and reconsideration of treatment preferences among families of children with rare diseases.MethodsWe used inductive content analysis of Respecting Choices Next Steps FAmily CEntered (FACE) pediatric advance care planning interviews and documents to describe parental treatment preferences in a hypothetical clinical scenario.ResultsEighteen parents across 14 interviews completed an advance care plan. In 13 of 14 advance care plans, parents indicated their preference was to continue all treatments. In 10 of 13 of those plans, parents indicated circumstances in which they would reconsider continuing all treatments which we described using 4 themes: having concerns about child's quality of life; after allowing some time to see; having certainty in child's decline; and being at peace.ConclusionsWhile almost all families who completed an advance care plan indicated preference to continue all treatments, most families would reconsider this plan in particular circumstances. Using language expressed by families described here may help providers and families communicate effectively around treatment plans, particularly among the understudied community of children with rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.